<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536106</url>
  </required_header>
  <id_info>
    <org_study_id>TPRX/POC/BMSC/AMIRST/1.0</org_study_id>
    <nct_id>NCT01536106</nct_id>
  </id_info>
  <brief_title>Rapid Delivery of Autologous Bone Marrow Derived Stem Cells in Acute Myocardial Infarction Patients.</brief_title>
  <acronym>AMIRST</acronym>
  <official_title>Intracoronary Infusion of Concentrated Autologous Bone Marrow Mononuclear Cells in Acute Myocardial Infarction Patients Utilizing a Novel Point-of-Care Device for Rapid-Delivery of Stem Cells (AMIRST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TotipotentRX Cell Therapy Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TotipotentRX Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TotipotentRX Cell Therapy Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the feasibility and safety of
      intracoronary administration of autologous bone marrow derived mononuclear cell product in
      patients at risk for clinically significant cardiac dysfunction following AMI.

      The secondary objective of the study is to assess the effect on cardiac function and infarct
      region perfusion. A concurrent placebo control patient group meeting eligibility but not
      receiving autologous bone marrow derived stem cells will be evaluated similar to the treated
      group to assess the rate of significant spontaneous improvement in cardiac function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emerging evidence indicate that progenitor stem cells derived from bone marrow can be used to
      improve cardiac function in acute myocardial infarction patients. There is a great potential
      for stem cell therapy, using a variety of cell precursors to contribute to new blood vessel
      formation and muscle preservation in the myocardial infarct zone. The administration of cells
      via an infusion through the infarct related artery appears to be feasible and result in a
      clinical effect in some studies. Across the globe AMI is the leading cause of morbidity and
      mortality. This cannot be prevented by optimal standard therapies i.e. balloon or stent
      dilation of the infarct vessels.

      The study is a double blind, placebo controlled, randomized, multicenter trial. Male or
      female patients between 18-75 years with first incidence of Acute Myocardial Infarction(AMI)
      and LVEF less than or equal to 40% are included in the study. Patients who have undergone
      successful percutaneous intervention (PCI) within ≤ 24 hours after onset of symptoms
      (PTCA/stent) or / and Thrombolysed patients having TIMI-3 flow are eligible to take part in
      the study.

      A total of 30 subjects will be recruited and randomly assigned to receive concentrated BMMNC
      or placebo. All patients will undergo bone marrow aspiration within 3-10 days from the index
      event(infarction). Bone Marrow(BM) will be processed utilizing point of care technology.
      Following cell processing, the concentrated BMMNC or placebo control is infused directly into
      the infarct related artery using the stop flow method. Clinical follow up for all the
      subjects at 1,30, 60, 90, 180 and 360 days will be performed from the day of the procedure,
      with primary and secondary end points evaluated for both study arms.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events as a measure of safety</measure>
    <time_frame>12 Months</time_frame>
    <description>Feasibility and safety of Intracoronary infusion of autologous BMMNCs processed through intraoperative point of care technology, freedom from arrhythmia's.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the global Left Ventricular Ejection Fraction(LVEF), LV volumes-End Systolic Volume (ESV) and End Diastolic Volume (EDV), infarct size, myocardial mass, myocardial viability and regional wall motion abnormalities.</measure>
    <time_frame>12 Months</time_frame>
    <description>Changes in the global Left Ventricular Ejection Fraction(LVEF), LV volumes-End Systolic Volume (ESV) and End Diastolic Volume (EDV), infarct size, myocardial mass, myocardial viability and regional wall motion abnormalities measured by Cardiac MRI and assessed by central Core lab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE)</measure>
    <time_frame>12 Months</time_frame>
    <description>MACE was defined as the composites of any cause of death, myocardial infarction, revascularization of the target vessel, re-hospitalization for heart failure, and life-threatening arrhythmia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 Months</time_frame>
    <description>Quality of life assessment is done using short-form 36, Minnesota living with heart failure questionnaire and Seattle Angina Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of bone marrow derived mononuclear cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of autologous peripheral blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous Bone marrow mononuclear cells</intervention_name>
    <description>Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>BMMNC treatment group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Intracoronary infusion of autologous peripheral blood.</description>
    <arm_group_label>Placebo Control</arm_group_label>
    <other_name>Placebo control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female of age 18 - 75 years

          -  Incidence of first myocardial infarction

          -  Acute STEMI with LV hypokinesia involving anteroseptal, lateral or inferior walls

          -  LVEF &lt; 40% pre-intervention

          -  Successful percutaneous intervention (PCI) within ≤ 24 hours after onset of symptoms
             (PTCA/stent) or / and Thrombolysed patients having TIMI-3 flow.

          -  Written informed consent

        Exclusion Criteria:

          -  Multi-vessel coronary disease requiring surgical intervention (CABG) or left main
             coronary artery disease &gt; 50% blockage

          -  Previous history of CABG

          -  Pulmonary edema

          -  Cardiogenic shock

          -  Myocarditis

          -  Renal or hepatic dysfunction

          -  Hematologic disease

        General Exclusion Criteria:

          -  Alcohol or drug dependency, active or uncontrolled acute myocarditis

          -  HIV, HBV, or HCV infections

          -  Evidence of malignant or hematological diseases

          -  Metal implants of any kind

          -  Claustrophobia

          -  Renal insufficiency

          -  History of bleeding disorder

          -  Anemia (haemoglobin &lt;8.5mg/dl)

          -  Platelet count &lt;100,000/ml
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Venkatesh Ponemone, PhD</last_name>
    <role>Study Director</role>
    <affiliation>TotipotentRX Cell Therapy Pvt. Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Harris, MS</last_name>
    <role>Study Chair</role>
    <affiliation>TotipotentRX Cell Therapy Pvt. Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashok Seth, FRCP, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fortis Escorts Heart Institute and Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Upendra Kaul, MD,DM, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fortis Flt. Lt. Rajan Dhall Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sreenivas A Kumar, MD, DM, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>CARE Hospitals, Hyderabad, India</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenneth Harris, MS</last_name>
    <phone>13234207766</phone>
    <email>ken.harris@totipotentrx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Venkatesh Ponemone, PhD</last_name>
    <phone>911244976860</phone>
    <email>ponemone@totipotentrx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CARE Hospitals, Banjara Hills</name>
      <address>
        <city>Hyderabad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sreenivas A Kumar</last_name>
      <phone>040-30418126</phone>
      <email>arramraj@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Sreenivas A Kumar, MD, DM, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Venkatesh Ponemone, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fortis Escorts Heart Institute and Research Centre</name>
      <address>
        <city>New Delhi</city>
        <zip>110025</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashok Seth, FRCS, FSCAI</last_name>
      <phone>911147134232</phone>
      <email>ashok.seth@fortishealthcare.com</email>
    </contact>
    <contact_backup>
      <last_name>Vinay Sanghi, MD</last_name>
      <phone>911147135000</phone>
      <email>vinay.sanghi@fortishealthcare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ashok Seth, FRCS, FSCAI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Upendra Kaul, MD, DM, FACC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vishal Rastogi, MD, DM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vinay Sanghi, FACP,FACC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mona Bhatia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Venkatesh Ponemone, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fortis Flt. Lt. Rajan Dhall Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Upendra Kaul, MD</last_name>
      <phone>911147135000</phone>
      <email>upendra.kaul@fortishealthcare.com</email>
    </contact>
    <contact_backup>
      <last_name>Tapan Ghose, MD</last_name>
      <phone>911147134232</phone>
      <email>tapan.ghose@fortishealthcare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Upendra Kaul, MD, DM, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tapan Ghose, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ripen Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ranjan Kachru, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mona Bhatia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Venkatesh Ponemone, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Roncalli J, Mouquet F, Piot C, Trochu JN, Le Corvoisier P, Neuder Y, Le Tourneau T, Agostini D, Gaxotte V, Sportouch C, Galinier M, Crochet D, Teiger E, Richard MJ, Polge AS, Beregi JP, Manrique A, Carrie D, Susen S, Klein B, Parini A, Lamirault G, Croisille P, Rouard H, Bourin P, Nguyen JM, Delasalle B, Vanzetto G, Van Belle E, Lemarchand P. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J. 2011 Jul;32(14):1748-57. doi: 10.1093/eurheartj/ehq455. Epub 2010 Dec 2.</citation>
    <PMID>21127322</PMID>
  </results_reference>
  <results_reference>
    <citation>Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail. 2010 Jul;12(7):721-9. doi: 10.1093/eurjhf/hfq095. Erratum in: Eur J Heart Fail. 2013 Mar;15(3):360.</citation>
    <PMID>20576835</PMID>
  </results_reference>
  <results_reference>
    <citation>Dohmann HF, Silva SA, Sousa AL, Braga AM, Branco RV, Haddad AF, Oliveira MA, Moreira RC, Tuche FA, Peixoto CM, Tura BR, Borojevic R, Ribeiro JP, Nicolau JC, Nóbrega AC, Carvalho AC. Multicenter double blind trial of autologous bone marrow mononuclear cell transplantation through intracoronary injection post acute myocardium infarction - MiHeart/AMI study. Trials. 2008 Jul 3;9:41. doi: 10.1186/1745-6215-9-41.</citation>
    <PMID>18598362</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <last_update_submitted>September 3, 2013</last_update_submitted>
  <last_update_submitted_qc>September 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell therapy, Bone marrow stem cells, cardiac cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

